Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 07, 2016 10:31 AM ET

Pharmaceuticals

Company Overview of POZEN Inc.

Executive Profile

Seth A. Rudnick M.D.

Director, Chairman of Nominating/Corporate Governance Committee and Member of Audit Committee, POZEN Inc.
AgeTotal Calculated CompensationThis person is connected to 13 Board Members in 13 different organizations across 21 different industries.

See Board Relationships
66$149,288

Background

Dr. Seth A. Rudnick, M.D., serves as the Chairman and Scientific and Clinical Advisor of G1 Therapeutics, Inc. since January 7, 2014. Dr. Rudnick has been the Chairman of Liquidia Technologies Inc. since March 11, 2008. He serves as the Chairman of ORTHOCON Inc, Drug Innovation Ventures at Emory (DRIVE) and Meryx Inc. He has been a Member of Board of Directors of Liquidia Technologies, Inc. since 2006, Square 1 Financial Inc. since November 2012, Pozen Inc. since July ...

Corporate Headquarters

1414 Raleigh Road
Chapel Hill, North Carolina 27517

United States

Phone: 919-913-1030
Fax: 919-913-1039

Board Members Memberships

Director
Director
Chairman
Director
2006-Present
Chairman
2008-Present
Chairman of the Board
2011-Present
Director, Chairman of Nominating/Corporate Governance Committee and Member of Audit Committee
2012-Present
Member of Board of Directors
2013-Present
Director
2014-Present
Chairman and Scientific and Clinical Advisor

Education

BA
The University of Pennsylvania
MD
University of Virginia
MD
Washington University, St. Louis
Post-Doctoral Training
Yale University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$69,292
Total Calculated Compensation$149,288
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Rajiv Kanishka Liyanaarchchie De Silva Chief Executive Officer, President and Director
Endo International plc
$1.1M
Daniel N. Swisher Jr.Chief Executive Officer, President and Director
Sunesis Pharmaceuticals, Inc.
$488.1K
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
$2.0M
Kenneth C. Frazier Chairman, Chief Executive Officer and President
Merck & Co. Inc.
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
$3.1M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact POZEN Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.